Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a cohort-controlled study

被引:38
作者
Lykissas, Marios G. [1 ]
Aichmair, Alexander [1 ]
Sama, Andrew A. [1 ]
Hughes, Alexander P. [1 ]
Lebl, Darren R. [1 ]
Cammisa, Frank P. [1 ]
Girardi, Federico P. [1 ]
机构
[1] Hosp Special Surg, Spine & Scoliosis Serv, Dept Orthoped Surg, Weill Cornell Med Coll, New York, NY 10021 USA
关键词
Nerve injury; LLIF; XLIF; rhBMP-2; Thigh pain; Transforming growth factor-beta; SPINAL-CORD; AXONAL GROWTH; REGENERATION; COMPLICATIONS; ARTHRODESIS; OUTCOMES; ACTIVATION; EXPRESSION; PROMOTES; GUIDANCE;
D O I
10.1016/j.spinee.2013.06.109
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
BACKGROUND CONTEXT: Despite common use of intraoperative electrophysiologic neuro-monitoring, injuries to the lumbar plexus during lateral lumbar interbody fusion (LLIF) have been reported. Emerging data suggest that recombinant human bone morphogenetic protein-2 (rhBMP-2) use during an anterior or transforaminal lumbar interbody fusion may be associated with an increased risk of neurological deficit. Clinical data on the sequelae of rhBMP-2 implantation in close proximity to the lumbosacral plexus during LLIF remains to be understood. PURPOSE: The purpose of this study was to compare the incidence of neurologic deficits and pain in patients undergoing LLIF with and without rhBMP-2. STUDY DESIGN/SETTING: Retrospective outcome analysis in controlled cohorts undergoing the lateral exposure technique for LLIF with and without rhBMP-2. METHODS: The electronic medical records of patients undergoing LLIF with and without supplemental posterior fusion for degenerative spinal conditions were retrospectively reviewed over a 6-year period. Patients with previous lumbar spine surgery or follow-up of less than 6 months were excluded. Patients were divided into 2 groups, Group 1 (rhBMP-2 use; n=72) and Group 2 (autograft/allograft use; n-72), and were matched according to the age at the time of surgery, gender, weight, body mass index, side of approach, total number of treated spinal segments, use of supplemental posterior fusion, and length of follow-up. RESULTS: Immediately after surgery, a sensory deficit was recorded in 33 patients in Group 1 and 35 patients in Group 2 (odds ratio [ OR] 0.895; 90% confidence interval [CI] 0.516-1.550; p=.739). At last follow-up, a persistent sensory deficit was identified in 29 patients whose LLIF procedurewas supplemented by rhBMP-2 and 20 patients in whom autograft/allograft was used (OR 1.754; 90% CI 0.976-3.151; p=.115). A motor deficit was recorded in 37 patients immediately after the rhBMP-2 procedure and 28 patients treated with autograft/allograft (OR 1.661; 90% CI 0.953-2.895; p=.133). A persistent motor deficit was recorded in 35 and 17 patients in Groups 1 and 2, respectively, at last follow-up (OR 3.060; 90% CI 1.681-5.571; p=.002). During the first postoperative examination, 37 patients in Group 1 and 25 patients in Group 2 complained of anterior thigh or groin pain (OR 1.987; 90% CI 1.133-3.488; p=.045). At last follow-up, there was a significantly higher number of patients in Group 1 who complained of persistent anterior thigh or groin pain than Group 2 (8 vs. 0 patients) (OR 16.470; 90% CI 1.477-183.700; p=.006). CONCLUSIONS: Our results provide evidence of an increased rate of postoperative neurologic deficit and anterior thigh/groin pain after LLIF using rhBMP-2, when compared with matched controls without rhBMP-2 exposure. This study suggests a potential direct deleterious effect of rhBMP2 on the lumbosacral plexus. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:217 / 224
页数:8
相关论文
共 46 条
[1]
[Anonymous], AIDS EX PER NERV SYS
[2]
Boden SD, 2005, ORTHOP NURS, V24, P49
[3]
Burkus JK, 2010, J BONE JOINT SURG AM, V92A, P2615
[4]
Influence of rhBMP-2 on the healing patterns associated with allograft interbody constructs in comparison with autograft [J].
Burkus, JK ;
Sandhu, HS ;
Gornet, MF .
SPINE, 2006, 31 (07) :775-781
[5]
A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned [J].
Carragee, Eugene J. ;
Hurwitz, Eric L. ;
Weiner, Bradley K. .
SPINE JOURNAL, 2011, 11 (06) :471-491
[6]
Retrograde ejaculation after anterior lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a 10-year cohort controlled study [J].
Comer, Garet C. ;
Smith, Micah W. ;
Hurwitz, Eric L. ;
Mitsunaga, Kyle A. ;
Kessler, Robert ;
Carragee, Eugene J. .
SPINE JOURNAL, 2012, 12 (10) :881-890
[7]
Alterations in Recovery from Spinal Cord Injury in Rats Treated with Recombinant Human Bone Morphogenetic Protein-2 for Posterolateral Arthrodesis [J].
Dmitriev, Anton E. ;
Castner, Suzanne ;
Lehman, Ronald A., Jr. ;
Ling, Geoffrey S. F. ;
Symes, Aviva J. .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2011, 93A (16) :1488-1499
[8]
Bone morphogenetic protein-2 and spinal arthrodesis: the basic science perspective on protein interaction with the nervous system [J].
Dmitriev, Anton E. ;
Lehman, Ronald A., Jr. ;
Symes, Aviva J. .
SPINE JOURNAL, 2011, 11 (06) :500-505
[9]
Food and Drug Administration, INFUSE MASTERGRAFT P
[10]
Complications with recombinant human bone morphogenetic protein-2 in posterolateral spine fusion associated with a dural tear [J].
Glassman, Steven D. ;
Gum, Jeffrey L. ;
Crawford, Charles H., III ;
Shields, Christopher B. ;
Carreon, Leah Y. .
SPINE JOURNAL, 2011, 11 (06) :522-526